

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

~~Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),~~

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient, with said dextran derivative being present at a unit dose of between 0.1 and 50 mg.

Claim 2 (canceled)

Claim 3 (currently amended): ~~The A process pharmaceutical composition as claimed in claim 1 wherein said composition has for preparing a medicament having an action on the healing of the gastric mucosa comprising the step of using the pharmaceutical composition as claimed in claim 1.~~

Claim 4 (currently amended): ~~The pharmaceutical composition process as claimed in claim 3, characterized wherein in that the unit dose of said dextran derivative is between 1.5 and 10 mg.~~

Claim 5 (currently amended): ~~The pharmaceutical composition process as claimed in claim 3 or claim 4, characterized in that wherein said pharmaceutical composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.~~

Claim 6 (currently amended): ~~The pharmaceutical composition process as claimed in any one of claims 3 to 5, characterized in that wherein said dextran derivative is enclosed in a vector.~~

Claim 7 (currently amended): The pharmaceutical composition process as claimed in any one of claims 3 to 6, characterized in thatwherein said pharmaceutical composition is adapted for oral administration.

Claim 8 (currently amended): A pharmaceutical composition as claim in claim 1 process for preparing a medicament wherein said composition having -an action on muscle healing ~~comprising the step of using the pharmaceutical composition as claimed in claim 1.~~

Claim 9 (currently amended): The pharmaceutical composition process as claimed in claim 8, characterized in thatwherein the unit dose of said dextran derivative is between 0.5 and 50 mg.

Claim 10 (currently amended): The pharmaceutical composition process as claimed in claim 8 or claim 9, characterized in thatwherein said pharmaceutical composition is present in the form of a gel, an ointment or an isotonic solution.

Claim 11 (currently amended): The pharmaceutical composition process as claimed in any one of claims 8 to 10, characterized in thatwherein said pharmaceutical composition is adapted to administration by local external application or by the parenteral route.

Claim 12 (currently amended): A pharmaceutical composition as claimed in claim 1, wherein said composition has process for preparing a medicament having an action on ocular healing ~~comprising the step of using the pharmaceutical composition as claimed in claim 1.~~

Claim 13 (currently amended): The pharmaceutical composition process as claimed in claim 12, characterized in thatwherein the unit dose of said dextran derivative is between 0.1 and 10 mg.

Claim 14 (currently amended): The pharmaceutical composition process as claimed in claim 12 or claim 13, characterized in thatwherein said pharmaceutical composition is present in the form of eye drops or an ophthalmic ointment.

Claim 15 (currently amended): A pharmaceutical composition which has an action on skin healing, which is adapted to topical administration and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide-dextran chain,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (~~sulfation of the free hydroxyl functions carried by the glucoside units~~),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a concentration of less than 10% (by weight/volume).

Claim 16 (canceled)

Claim 17 (currently amended): The process-pharmaceutical composition as claimed in claim 16, characterized in thatwherein said pharmaceutical composition is present in the form of a paste, an ointment, an aqueous liquid, an oily liquid, an aqueous gel, an oily gel, an aerosol, a foam, a microemulsion, a multiple emulsion, liposomes or nanoparticles.

Claim 18 (currently amended): A pharmaceutical composition which has an anticomplementary action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide-dextran chain,
MC represents methylcarboxylate groups,
B represents carboxymethylbenzylamide groups,
Su represents sulfate groups (~~sulfation of the free hydroxyl functions carried by the glucoside units~~),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.3 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.4,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,
with said dextran derivative being present at a unit dose of between 5 and 30 mg.

Claim 19 (canceled)

Claim 20 (currently amended): The pharmaceutical composition process as claimed in claim 19, ~~characterized in that wherein~~ said pharmaceutical composition is present in the form of an isotonic solution.

Claim 21 (original): A dressing, characterized in that it is soaked with the pharmaceutical composition as claimed in claim 15.

Claim 22-24 (canceled)

Remarks

Reconsideration and further examination of the above-identified patent application in light of the present Amendment, Reply, and Remarks is respectfully requested.

Authorization is hereby given to charge any deficiency in fees or any other fees in connection with the above-identified patent application to our Deposit Account No. 23-0920.